Our firm is aggressively litigating Zofran birth defect cases including: heart defects, club foot, cleft lip, cleft palate, skull deformities and extra digits. Zofran (Ondansetron) is an anti-nausea drug that may cause birth defects. Studies and literature are proving greater links between a Zofran and birth defects - a drug classified as a serotonin (5-HT3) receptor antagonist. This drug was originally used to treat and prevent chemotherapy and radiotherapy induced nausea and. It was later used to treat and sometimes to prevent severe morning sickness during pregnancy.
Within the product labeling for Zofran (sold by GlaxoSmithKline), there is no warning of increased risks of birth defects. If you know an infant suffering from birth defects after the mother took Zofran during pregnancy, the lawyers at Rheingold Giuffra Ruffo & Plotkin LLP are here to help them explore their legal options. Paul Rheingold has extensive litigation experience with the following drugs associated with birth defects: Celexa, Clomid, DES (Diethylstilbestrol), Diflucan, Lexapro, Paxil, Wellbutrin and Zoloft.
At Rheingold Giuffra Ruffo & Plotkin LLP, we have been helping people from New York and across the nation with their most critical legal problems for over 30 years. We are handling a wide range of drug liability claims, including those involving the prescription drugs which are implicated with birth defects.
Suspected Birth Defects from Zofran include:
- Heart defects
- Club foot
- Polydactyly (extra digits)
- Cleft lip
- Cleft palate
- Craniosynostosis (skull deformities)
Although the FDA only approved Zofran for cancer patients, GlaxoSmithKline marketed Zofran to pregnant women suffering from morning sickness. The FDA never approved Zofran for use by pregnant women and GlaxoSmithKline never tested Zofran for use by pregnant woman.
In the largest settlement involving a pharmaceutical company to date in 2012, Glaxo was sued for its actions regarding Zofran and other drugs. Glaxo pleaded guilty in 2012 to federal charges of fraud and illegal promotion of drugs. The charges included selling drugs for unapproved uses, improper marketing and failing to report safety data. As part of a settlement Glaxo agreed to pay $3 billion.
Court discovery documents revealed Glaxo knew for years that Zofran posed an unreasonable risk of harm to developing babies because it passes through the placenta. The drug is especially dangerous if used during the first trimester. Despite this knowledge Glaxo continued to market the drug to pregnant women.
Our attorneys will work with you personally to determine the extent of the monetary damage this drug has caused you, and what legal remedies are at your disposal. Our goal is to help you obtain monetary compensation for the financial hardships you face.
The JPML has centralized the Zofran Multi-District Litigation before the Honorable Dennis Saylor in the District of Massachusetts. We are pleased with the selection as Judge Saylor is a very capable and fair Judge. The District of Massachusetts is also a good venue for this case.
The consolidation of these lawsuits is an important step in resolving the Zofran litigation. An MDL is not the same as a class action because each case retains its independent status but pre-trial matters, such as discovery, are handled together with other cases. This streamlines the litigation process and makes it cost effective. Our lawyers have handled hundreds of MDL cases and we can help you resolve your Zofran claim.